Life Science Company News

Allocation of Share Options

NASDAQ Copenhagen

Report on transactions of executives and related parties in Coloplast shares and related securities.

According to the Market Abuse Regulation art. 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities.

The below transaction deals with allocation of share options:

NameLars Rasmussen
ReasonCEO
IssuerColoplast A/S
ISIN codeDK0060448595
DescriptionShare options
TransactionShare option allocation
Trade date22 January 2018
MarketNASDAQ Copenhagen
Number93,885
Black & Scholes value per share option DKK57.78
Market value in DKK5,424,675
Strike price per share519.40


NameAnders Lonning-Skovgaard
ReasonExecutive Vice President
IssuerColoplast A/S
ISIN codeDK0010309657
DescriptionShare options
TransactionShare option allocation
Trade date22 January 2018
MarketNASDAQ Copenhagen
Number38,939
Black & Scholes value per share option DKK57.78
Market value in DKK2,249,895
Strike price per share519.40


NameKristian Villumsen
ReasonExecutive Vice President
IssuerColoplast A/S
ISIN codeDK0060448595
DescriptionShare options
TransactionShare option allocation
Trade date22 January 2018
MarketNASDAQ Copenhagen
Number49,106
Black & Scholes value per share option DKK57.78
Market value in DKK2,837,345
Strike price per share519.40


NameAllan Rasmussen
ReasonExecutive Vice President
IssuerColoplast A/S
ISIN codeDK0010309657
DescriptionShare options
TransactionShare option allocation
Trade date22 January 2018
MarketNASDAQ Copenhagen
Number39,371
Black & Scholes value per share option DKK57.78
Market value in DKK2,274,856
Strike price per share519.40

Calculation of value:

When calculating the value of share options the Black & Scholes formula is applied. The formula is described in Coloplast’s annual report.

The strike price is calculated on basis of the average price for all tradings on 29 December 2017 plus 5%.

Kind regards,
Coloplast A/S

Anne-Sofie Søegaard

This information is available in Danish and in English, in case of doubt the Danish version prevails.

For further information: Anne-Sofie Søegaard, tel. +45 49 11 18 00.

http://prlibrary-eu.nasdaq.com/Resource/Download/bf24c6aa-c210-416f-8bcd-04a783c9f25e

By: Nasdaq / GlobeNewswire - 22 Jan 2018
Back to overview

Enhance your business development with Biotechgate